| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2025―Okt―14 |
A Novel Fluorescence Polarization Binding Assay for the Main Protease (Mpro) of SARS-CoV-2 |
Mackenzie K. Wyllie, Rayhan G. Biswas, Jyoti Vishwakarma, Morgan A. Esler, Joseph A. Rollie, Hideki Aihara, Reuben S. Harris, Daniel A. Harki |
| 2 |
[GO] |
2025―Sep―11 |
A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID |
David Fineberg, Alain Moreau, Elena K. Schneider-Futschik, Christopher W. Armstrong |
| 3 |
[GO] |
2025―Apr―25 |
Discovery of SARS-CoV-2 Nsp14-Methyltransferase (MTase) Inhibitors by Harnessing Scaffold-Centric Exploration of the Ultra Large Chemical Space |
Sourav Pal, Quinlin M. Hanson, Sarah C. Ogden, Emily M. Lee, Natalia J. Martinez, Alexey V. Zakharov |
| 4 |
[GO] |
2025―Mrz―19 |
Spike Protein-Fibrinogen Interaction: A Novel Immune Evasion Strategy of SARS-CoV-2? |
Saroj Kumar Panda, Shashi Singh, Parth Sarthi Sen Gupta |
| 5 |
[GO] |
2025―Feb―26 |
Development of a Fluorescence Polarization Assay for the SARS-CoV-2 Papain-like Protease |
Kan Li, Prakash Jadhav, Yu Wen, Haozhou Tan, Jun Wang |
| 6 |
[GO] |
2025―Feb―21 |
Immuno-μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints |
Julian Guercetti, Marc Alorda, Luciano Sappia, Roger Galve, Macarena Duran-Corbera, Daniel Pulido, Ginevra Berardi, Miriam Royo, Alicia Lacoma, José Muñoz, Eduardo Padilla, Silvia Castañeda, Elena Sendra, Juan P. Horcajada, Agustín Gutierrez-Galvez, Santiago Marco, J.-Pablo Salvador, M.-Pilar Marco |
| 7 |
[GO] |
2025―Feb―04 |
Alcohol Consumption Modulates the Development of Chronic Pain in COVID-19 Patients: A Network Meta-Analysis |
Muhammed Bishir, Michael Vigorito, Ming-Huan Chan, Mohammed A S Khan, Sulie L. Chang |
| 8 |
[GO] |
2024―Nov―19 |
Screened Fv-Antibodies against the Angiotensin-Converting Enzyme 2 (ACE2) Receptor Neutralizing the Infection of SARS-CoV-2 |
Jaeyong Jung, Soonil Kwon, Jeong Soo Sung, Hyung Eun Bae, Min-Jung Kang, Joachim Jose, Misu Lee, Jae-Chul Pyun |
| 9 |
[GO] |
2024―Nov―05 |
Repurposing Drugs and Synergistic Combinations as Potential Therapies for Inhibiting SARS-CoV-2 and Coronavirus Replication |
Richard Boulon, Clément Mazeaud, Majid D. Farahani, Mathilde Broquière, Mustapha Iddir, Tania Charpentier, Anaïs Anton, Yann Ayotte, Simon Woo, Alain Lamarre, Laurent Chatel-Chaix, Steven R. LaPlante |
| 10 |
[GO] |
2024―Okt―04 |
Thiol-Reactive or Redox-Active: Revising a Repurposing Screen Led to a New Invalidation Pipeline and Identified a True Noncovalent Inhibitor Against Papain-like Protease from SARS-CoV-2 |
Maria Kuzikov, Stefano Morasso, Jeanette Reinshagen, Markus Wolf, Vittoria Monaco, Flora Cozzolino, Simona Golič Grdadolnik, Primož Šket, Janez Plavec, Daniela Iaconis, Vincenzo Summa, Francesca Esposito, Enzo Tramontano, Maria Monti, Andrea R. Beccari, Björn Windshügel, Philip Gribbon, Paola Storici, Andrea Zaliani |
| 11 |
[GO] |
2024―Okt―02 |
Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease |
Jian Xue, Hongtao Li, Ruyu Wang, Meiting Wang, Xixiang Chen, Yaqi Deng, Jiani Lu, Yexi Li, Yuheng Song, Jianrong Xu, Tong Zhu, Lili Chen, Shunying Liu |
| 12 |
[GO] |
2024―Sep―12 |
Evaluation of Angiotensin-Converting Enzyme 2 Expression In Vivo with Novel 68Ga-Labeled Peptides Originated from the Coronavirus Receptor-Binding Domain |
Linlin Li, Rongxi Wang, Li He, Hua Guo, Lei Fu, Guochang Wang, Jiarou Wang, Ziying Chen, Xingtong Peng, Xinyu Lu, Huimin Sui, Yuanyuan Jiang, Jie Zang, Lianghui Gao, Zhaohui Zhu |
| 13 |
[GO] |
2024―Mrz―21 |
Screening Peptide Drug Candidates To Neutralize Whole Viral Agents: A Case Study with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |
Cemile Elif Özçelik, Cemre Zekiye Araz, Özgür Yılmaz, Sevgi Gülyüz, Pınar Özdamar, Ezgi Salmanlı, Aykut Özkul, Urartu Özgür Şafak Şeker |
| 14 |
[GO] |
2024―Mrz―06 |
Correction to “Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity” |
Philipp Flury, Julian Breidenbach, Nadine Krüger, Rabea Voget, Laura Schäkel, Yaoyao Si, Vesa Krasniqi, Sara Calistri, Matthias Olfert, Katharina Sylvester, Cheila Rocha, Raphael Ditzinger, Alexander Rasch, Stefan Pöhlmann, Thales Kronenberger, Antti Poso, Katharina Rox, Stefan A. Laufer, Christa E. Müller, Michael Gütschow, Thanigaimalai Pillaiyar |
| 15 |
[GO] |
2024―Feb―01 |
Neutralization of SARS-CoV-2 and Intranasal Protection of Mice with a nanoCLAMP Antibody Mimetic |
Quentin Pagneux, Nathalie Garnier, Manon Fabregue, Sarah Sharkaoui, Sophie Mazzoli, Ilka Engelmann, Rabah Boukherroub, Mary Strecker, Eric Cruz, Peter Ducos, Sabine Szunerits, Ana Zarubica, Richard Suderman |
| 16 |
[GO] |
2024―Jan―19 |
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity |
Philipp Flury, Julian Breidenbach, Nadine Krüger, Rabea Voget, Laura Schäkel, Yaoyao Si, Vesa Krasniqi, Sara Calistri, Matthias Olfert, Katharina Sylvester, Cheila Rocha, Raphael Ditzinger, Alexander Rasch, Stefan Pöhlmann, Thales Kronenberger, Antti Poso, Katharina Rox, Stefan A. Laufer, Christa E. Müller, Michael Gütschow, Thanigaimalai Pillaiyar |
| 17 |
[GO] |
2024―Jan―16 |
Methotrexate Inhibits the Binding of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Receptor Binding Domain to the Host-Cell Angiotensin-Converting Enzyme-2 (ACE-2) Receptor |
Soo-Kyung Kim, Sartanee Suebka, Adley Gin, Phuong-Diem Nguyen, Yisha Tang, Judith Su, William A. Goddard |
| 18 |
[GO] |
2023―Dez―13 |
Levels of Angiotensin and Kinin Metabolite Peptides Related to COVID-19 Severity |
Ben K. Ahiadu, Ami Grunbaum, Nicholas Rozza, Richard B. Kremer, James F. Rusling |
| 19 |
[GO] |
2023―Sep―06 |
Emerging Landscape of Preclinical Models for Studying COVID-19 Neurologic Diseases |
Jason Li, Jing Wang, Hu Wang |
| 20 |
[GO] |
2023―Aug―04 |
Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19 |
Ke-Wei Zhu |
| 21 |
[GO] |
2023―Jul―03 |
Messenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19? |
Dongqiao Li, Cynthia Liu, Yingzhu Li, Rumiana Tenchov, Janet M. Sasso, Di Zhang, Dan Li, Lixue Zou, Xuezhao Wang, Qiongqiong Zhou |
| 22 |
[GO] |
2023―Jun―05 |
Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus |
Xuemei Feng, Hu Wang |
| 23 |
[GO] |
2023―Mai―22 |
Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus |
Fabiana Renzi, Austin Seamann, Koelina Ganguly, Kabita Pandey, Siddappa N. Byrareddy, Surinder Batra, Sushil Kumar, Dario Ghersi |
| 24 |
[GO] |
2023―Mrz―07 |
Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7 |
Yushu Gu, Miaomiao Liu, Bart L. Staker, Garry W. Buchko, Ronald J. Quinn |
| 25 |
[GO] |
2023―Feb―27 |
Association of COVID-19 with Comorbidities: An Update |
Sayan Chatterjee, Lakshmi Vineela Nalla, Monika Sharma, Nishant Sharma, Aditya A. Singh, Fehmina Mushtaque Malim, Manasi Ghatage, Mohd Mukarram, Abhijeet Pawar, Nidhi Parihar, Neha Arya, Amit Khairnar |
| 26 |
[GO] |
2022―Dez―28 |
Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies |
Chamandi S. Dampalla, Harry Nhat Nguyen, Athri D. Rathnayake, Yunjeong Kim, Krishani Dinali Perera, Trent K. Madden, Hayden A. Thurman, Alexandra J. Machen, Maithri M. Kashipathy, Lijun Liu, Kevin P. Battaile, Scott Lovell, Kyeong-Ok Chang, William C. Groutas |
| 27 |
[GO] |
2022―Dez―23 |
Detailed Insights into the Inhibitory Mechanism of New Ebselen Derivatives against Main Protease (Mpro) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) |
Pritiranjan Sahoo, Dipti Ranjan Lenka, Monojit Batabyal, Pritam Kumar Pain, Sangit Kumar, Debasish Manna, Atul Kumar |
| 28 |
[GO] |
2022―Jun―22 |
Enzyme Nanoscale Interactions with Manganese Zinc Sulfide Give Insight into Potential Antiviral Mechanisms and SARS-CoV-2 Inhibition |
Robert K. DeLong, Hanah Huber, Cesar Aparicio-Lopez, Abeera Bhatti, Ryan Swanson, Tej B. Shrestha, Natasha N. Gaudreault |
| 29 |
[GO] |
2022―Mai―23 |
Different Aspects of Emetine’s Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19 |
Mehdi Valipour |
| 30 |
[GO] |
2022―Apr―04 |
Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor |
Jens Glaser, Ada Sedova, Stephanie Galanie, Daniel W. Kneller, Russell B. Davidson, Elvis Maradzike, Sara Del Galdo, Audrey Labbé, Darren J. Hsu, Rupesh Agarwal, Dmytro Bykov, Arnold Tharrington, Jerry M. Parks, Dayle M. A. Smith, Isabella Daidone, Leighton Coates, Andrey Kovalevsky, Jeremy C. Smith |
| 31 |
[GO] |
2022―Apr―01 |
Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities |
Angela Corona, Krzysztof Wycisk, Carmine Talarico, Candida Manelfi, Jessica Milia, Rolando Cannalire, Francesca Esposito, Philip Gribbon, Andrea Zaliani, Daniela Iaconis, Andrea R. Beccari, Vincenzo Summa, Marcin Nowotny, Enzo Tramontano |
| 32 |
[GO] |
2022―Feb―14 |
Allosteric Site of ACE-2 as a Drug Target for COVID-19 |
Kunal Dutta |
| 33 |
[GO] |
2022―Jan―25 |
Experimental Model of Pulmonary Inflammation Induced by SARS-CoV-2 Spike Protein and Endotoxin |
Manoj Puthia, Lloyd Tanner, Ganna Petruk, Artur Schmidtchen |
| 34 |
[GO] |
2022―Jan―24 |
Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors |
Chunlong Ma, Jun Wang |
| 35 |
[GO] |
2022―Jan―03 |
SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening |
Kirill Gorshkov, Desarey Morales Vasquez, Kevin Chiem, Chengjin Ye, Bruce Nguyen Tran, Juan Carlos de la Torre, Thomas Moran, Catherine Z. Chen, Luis Martinez-Sobrido, Wei Zheng |
| 36 |
[GO] |
2021―Sep―17 |
Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants |
Sankalp Jain, Daniel C. Talley, Bolormaa Baljinnyam, Jun Choe, Quinlin Hanson, Wei Zhu, Miao Xu, Catherine Z. Chen, Wei Zheng, Xin Hu, Min Shen, Ganesha Rai, Matthew D. Hall, Anton Simeonov, Alexey V. Zakharov |
| 37 |
[GO] |
2021―Sep―06 |
Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells |
Rafael R. G. Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, Alessandra L. Leal, João Renato R. Pinho, Luis C. S. Ferreira, Henning Ulrich, Edison L. Durigon, Cristiane Rodrigues Guzzo |
| 38 |
[GO] |
2021―Jul―29 |
Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein |
Devivasha Bordoloi, Ziyang Xu, Michelle Ho, Mansi Purwar, Pratik Bhojnagarwala, Joel Cassel, Leila B. Giron, Susanne Walker, Abhijeet J Kulkarni, Edgar Tello Ruiz, Jihae Choi, Faraz I. Zaidi, Yuanhan Wu, Shaoying Wang, Ami Patel, Stephanie Ramos, Trevor Smith, Daniel Kulp, Kenneth E. Ugen, Alagarsamy Srinivasan, Mohamed Abdel-Mohsen, Laurent Humeau, David B. Weiner, Kar Muthumani |
| 39 |
[GO] |
2021―Jun―09 |
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir |
Zilei Xia, Michael Sacco, Yanmei Hu, Chunlong Ma, Xiangzhi Meng, Fushun Zhang, Tommy Szeto, Yan Xiang, Yu Chen, Jun Wang |
| 40 |
[GO] |
2021―Apr―29 |
Correction to “Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir” |
Ting Chen, Cheng-Yin Fei, Yi-Ping Chen, Karen Sargsyan, Jian-Jong Liang, Chun-Che Liao, Yi-Ling Lin, Chun-Ping Chang, Hanna S. Yuan, Carmay Lim |
| 41 |
[GO] |
2021―Apr―16 |
Identification of Novel MicroRNAs Targeting SARS-CoV-2 through the Regulation of TMPRSS2/PI3K/AKT/PTEN Alignment in Lung Cancer: An in Silico Analysis |
Debasmita Mukhopadhyay, Nour AlSawaftah, Ghaleb A Husseini |
| 42 |
[GO] |
2021―Apr―02 |
Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19 |
Xin Hu, Jonathan H. Shrimp, Hui Guo, Miao Xu, Catherine Z. Chen, Wei Zhu, Alexey V. Zakharov, Sankalp Jain, Paul Shinn, Anton Simeonov, Matthew D. Hall, Min Shen |
| 43 |
[GO] |
2021―Mrz―26 |
Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir |
Ting Chen, Cheng-Yin Fei, Yi-Ping Chen, Karen Sargsyan, Chun-Ping Chang, Hanna S. Yuan, Carmay Lim |
| 44 |
[GO] |
2021―Mrz―22 |
Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications |
Tessa M. Firestone, Opeoluwa O. Oyewole, St Patrick Reid, Caroline L. Ng |
| 45 |
[GO] |
2021―Mrz―19 |
COVID-19: Is There a Link between Alcohol Abuse and SARS-CoV-2-Induced Severe Neurological Manifestations? |
Jibran Sualeh Muhammad, Ruqaiyyah Siddiqui, Naveed Ahmed Khan |
| 46 |
[GO] |
2021―Mrz―17 |
A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics |
Jonas Gossen, Simone Albani, Anton Hanke, Benjamin P. Joseph, Cathrine Bergh, Maria Kuzikov, Elisa Costanzi, Candida Manelfi, Paola Storici, Philip Gribbon, Andrea R. Beccari, Carmine Talarico, Francesca Spyrakis, Erik Lindahl, Andrea Zaliani, Paolo Carloni, Rebecca C. Wade, Francesco Musiani, Daria B. Kokh, Giulia Rossetti |
| 47 |
[GO] |
2021―Mrz―11 |
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen |
Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, Andrea Zaliani |
| 48 |
[GO] |
2021―Mrz―04 |
COVID-19: Does SARS-CoV-2 Modulate Acanthamoeba Epigenetics to Enhance Survival and Transmission in the Environment? |
Jibran Sualeh Muhammad, Ruqaiyyah Siddiqui, Naveed Ahmed Khan |
| 49 |
[GO] |
2021―Mrz―01 |
Toward the Next-Generation COVID-19 Vaccines That Circumvent Antigenic Drift while Defusing Viral Infection |
Ariel Fernández |
| 50 |
[GO] |
2021―Feb―05 |
SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen |
Ariel Fernández |
| 51 |
[GO] |
2021―Jan―29 |
Docking Prediction of Levodopa in the Receptor Binding Domain of Spike Protein of SARS-CoV-2 |
Abdul Mannan Baig, Areeba Khaleeq, Hira Syeda, Noor Bibi |
| 52 |
[GO] |
2021―Jan―21 |
Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase |
Ariel Fernández |
| 53 |
[GO] |
2021―Jan―15 |
Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2 |
Roger M. Pallares, Rebecca J. Abergel |
| 54 |
[GO] |
2021―Jan―10 |
SARS-CoV-2, Hypoxia, and Calcium Signaling: The Consequences and Therapeutic Options |
Chhanda Charan Danta |
| 55 |
[GO] |
2020―Dez―31 |
COVID-19 Evolution in the Post-Vaccination Phase: Endemic or Extinct? |
Ariel Fernández |
| 56 |
[GO] |
2020―Dez―30 |
Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model |
Prashant Dogra, Javier Ruiz-Ramírez, Kavya Sinha, Joseph D. Butner, Maria J. Peláez, Manmeet Rawat, Venkata K. Yellepeddi, Renata Pasqualini, Wadih Arap, H. Dirk Sostman, Vittorio Cristini, Zhihui Wang |
| 57 |
[GO] |
2020―Dez―29 |
Antibacterial and Antiviral Functional Materials: Chemistry and Biological Activity toward Tackling COVID-19-like Pandemics |
Bhuvaneshwari Balasubramaniam, Sudhir Ranjan, Mohit Saraf, Prasenjit Kar, Surya Pratap Singh, Vijay Kumar Thakur, Anand Singh, Raju Kumar Gupta |
| 58 |
[GO] |
2020―Dez―12 |
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial |
Leticia R. Cruz, Idania Baladrón, Aliusha Rittoles, Pablo A. Díaz, Carmen Valenzuela, Raúl Santana, Maria M. Vázquez, Ariadna García, Deyli Chacón, Delvin Thompson, Gustavo Perera, Ariel González, Rafael Reyes, Loida Torres, Jesus Pérez, Yania Valido, Ralysmay Rodriguez, Dania M. Vázquez-Bloomquist, Mauro Rosales, Ailyn C. Ramón, George V. Pérez, Gerardo Guillén, Verena Muzio, Yasser Perera, Silvio E. Perea |
| 59 |
[GO] |
2020―Dez―09 |
Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis |
Debasmita Mukhopadhyay, Nour AlSawaftah, Ghaleb A. Husseini |
| 60 |
[GO] |
2020―Dez―01 |
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19 |
Bapurao Surnar, Mohammad Z. Kamran, Anuj S. Shah, Shanta Dhar |
| 61 |
[GO] |
2020―Nov―17 |
Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay |
Quinlin M. Hanson, Kelli M. Wilson, Min Shen, Zina Itkin, Richard T. Eastman, Paul Shinn, Matthew D. Hall |
| 62 |
[GO] |
2020―Nov―11 |
Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2 |
Ke Liu, Rongfeng Zou, Wenqiang Cui, Meiqing Li, Xueying Wang, Junlin Dong, Hongchun Li, Hongpei Li, Peihui Wang, Ximing Shao, Wu Su, H. C. Stephen Chan, Hongchang Li, Shuguang Yuan |
| 63 |
[GO] |
2020―Nov―07 |
Probing the Dynamic Structure-Function and Structure-Free Energy Relationships of the Coronavirus Main Protease with Biodynamics Theory |
Hongbin Wan, Vibhas Aravamuthan, Robert A. Pearlstein |
| 64 |
[GO] |
2020―Nov―03 |
Docking Prediction of Amantadine in the Receptor Binding Domain of Spike Protein of SARS-CoV-2 |
Abdul Mannan Baig, Areeba Khaleeq, Hira Syeda |
| 65 |
[GO] |
2020―Okt―19 |
Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles |
Catherine Z. Chen, Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer D. Petersen, Marco R. Straus, Wei Zhu, Paul Shinn, Hui Guo, Min Shen, Carleen Klumpp-Thomas, Samuel G. Michael, Joshua Zimmerberg, Wei Zheng, Gary R. Whittaker |
| 66 |
[GO] |
2020―Okt―15 |
Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario |
Ariel Fernández |
| 67 |
[GO] |
2020―Okt―14 |
Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19 |
Giovanni Bocci, Steven B. Bradfute, Chunyan Ye, Matthew J. Garcia, Jyothi Parvathareddy, Walter Reichard, Surekha Surendranathan, Shruti Bansal, Cristian G. Bologa, Douglas J. Perkins, Colleen B. Jonsson, Larry A. Sklar, Tudor I. Oprea |
| 68 |
[GO] |
2020―Okt―09 |
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors |
Chunlong Ma, Yanmei Hu, Julia Alma Townsend, Panagiotis I. Lagarias, Michael Thomas Marty, Antonios Kolocouris, Jun Wang |
| 69 |
[GO] |
2020―Okt―09 |
Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid |
Kirill Gorshkov, Catherine Z. Chen, Miao Xu, Juan Carlos de la Torre, Luis Martinez-Sobrido, Thomas Moran, Wei Zheng |
| 70 |
[GO] |
2020―Sep―30 |
Helminths and COVID-19 Co-Infections: A Neglected Critical Challenge |
Amir Abdoli |
| 71 |
[GO] |
2020―Sep―28 |
Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19 |
Parth Sarthi Sen Gupta, Malay Kumar Rana |
| 72 |
[GO] |
2020―Sep―28 |
Heme/Hemeoxygenase-1 System Is a Potential Therapeutic Intervention for COVID-19 Patients with Severe Complications |
Biplab K Maiti |
| 73 |
[GO] |
2020―Sep―18 |
SARS-CoV-2 vaccine development: An overview and perspectives |
Yi Liu, Kai Wang, Tarik F. Massoud, Ramasamy Paulmurugan |
| 74 |
[GO] |
2020―Sep―15 |
Achilles’ Heel of SARS-CoV-2 Structure |
Ariel Fernández |
| 75 |
[GO] |
2020―Sep―08 |
Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity? |
Aditya K. Padhi, Timir Tripathi |
| 76 |
[GO] |
2020―Sep―07 |
An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 |
Jonathan H. Shrimp, Stephen C. Kales, Philip E. Sanderson, Anton Simeonov, Min Shen, Matthew D. Hall |
| 77 |
[GO] |
2020―Sep―04 |
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening |
Wei Zhu, Miao Xu, Catherine Z. Chen, Hui Guo, Min Shen, Xin Hu, Paul Shinn, Carleen Klumpp-Thomas, Samuel G. Michael, Wei Zheng |
| 78 |
[GO] |
2020―Sep―01 |
Therapeutically Targeted Destabilization of the Quaternary Structure of the Spike Protein in the Dominant G614 Strain of SARS-CoV-2 |
Ariel Fernández |
| 79 |
[GO] |
2020―Aug―27 |
Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19 |
Dhanusha Nalawansha, Kusal Samarasinghe |
| 80 |
[GO] |
2020―Aug―18 |
Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection |
Chhanda Charan Danta |
| 81 |
[GO] |
2020―Aug―04 |
Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication? |
Biplab K Maiti |
| 82 |
[GO] |
2020―Jul―30 |
Potential therapeutic agents and associated bioassay data for COVID-19 and related human coronavirus infections |
Qiongqiong Zhou, Junko Kato-Weinstein, Yingzhu Li, Yi Deng, Roger Granet, Linda Garner, Cynthia Yu Liu, Dmitrii Polshakov, Chris Gessner, Steven Watkins |
| 83 |
[GO] |
2020―Jul―24 |
Potential Role of Peptide-Based Antiviral Therapy Against SARS-CoV-2 Infection |
Biplab K. Maiti |
| 84 |
[GO] |
2020―Jul―23 |
SARS-CoV-2 receptor ACE2 is enriched in a subpopulation of mouse tongue epithelial cells in non-gustatory papillae, but not in taste buds or embryonic oral epithelium |
Zhonghou Wang, Jingqi Zhou, Brett Marshall, Romdhane Rekaya, Kaixiong Ye, Hong-Xiang Liu |
| 85 |
[GO] |
2020―Jun―16 |
The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19 |
Sherif Elnagdy, Maha AlKhazindar |
|
